Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Change in Accured Expenses (2016 - 2025)

Palisade Bio has reported Change in Accured Expenses over the past 16 years, most recently at $677000.0 for Q4 2025.

  • Quarterly Change in Accured Expenses rose 147.99% to $677000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $576000.0 through Dec 2025, up 1128.57% year-over-year, with the annual reading at $576000.0 for FY2025, 1128.57% up from the prior year.
  • Change in Accured Expenses was $677000.0 for Q4 2025 at Palisade Bio, up from -$1.3 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $1.8 million in Q2 2025 and troughed at -$1.3 million in Q3 2025.
  • The 5-year median for Change in Accured Expenses is $75000.0 (2024), against an average of $24647.1.
  • The largest YoY upside for Change in Accured Expenses was 2318.67% in 2025 against a maximum downside of 914.29% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$8000.0 in 2021, then tumbled by 3737.5% to -$307000.0 in 2022, then plummeted by 74.27% to -$535000.0 in 2023, then soared by 151.03% to $273000.0 in 2024, then surged by 147.99% to $677000.0 in 2025.
  • Per Business Quant, the three most recent readings for PALI's Change in Accured Expenses are $677000.0 (Q4 2025), -$1.3 million (Q3 2025), and $1.8 million (Q2 2025).